Oak Ridge, TN – April 15, 2025 — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced compelling new data presented at the American College of Cardiology (ACC) 74th Annual Scientific Session and Expo held in Chicago from March 29-31st. Research from The Minneapolis Heart Institute Foundation® and Allina Health Minneapolis Heart Institute® demonstrated that hospitalized heart failure patients who received blood volume analysis (BVA) prior to hospital discharge could be used to stratify those with a  substantially better survival rate.

The study, “Radiolabeled Blood Volume Analysis during Hospitalization for Acute Decompensated Heart Failure and 1-Year Mortality,” presented by Hailey Miedema, research intern, Minneapolis Heart Institute Foundation, evaluated 1,237 hospitalized heart failure patients, including 202 who underwent BVA testing within two days of discharge.

Key findings:

• Patients confirmed as “euvolemic” (normal blood volume) through BVA showed markedly improved one-year survival rates
• In a Kaplan-Meier survival study, a hazard ratio, the risk of the event (in this case, death), is 2.61 times higher in the control group who were hypervolemic (congested) compared to the euvolemic group which BVA could uniquely identify
• This clinically significant hazard ratio quantifies survival differences across the entire follow-up period, accounting for both event occurrence and timing and had a very strong statistically significant p-value of 0.002
• The direct correlation between blood volume status and survival outcomes persisted even after adjusting for comorbidities
• Results strongly support the clinical value of objective blood volume measurement before discharging patients with acute decompensated heart failure to ensure successful treatment to euvolemia which only the BVA test was able to determine

Co- investigator Peter M. Eckman, MD, researcher at the Minneapolis Heart Institute Foundation and cardiologist and heart failure section head at the Allina Health Minneapolis Heart Institute, stated, “BVA is a great tool to ensure proper decongestion before discharge. This research indicates heart failure patients who achieve BVA-measured euvolemia experience higher one-year survival compared to those with hypervolemia.”